title: Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma.
abstract: OBJECTIVE
  To evaluate quality of life (QOL) and outcome of patients with anal carcinoma treated with short split-course chemoradiation (CRT).
  
  
  METHODS
  From 1991 to 2005, 58 patients with anal cancer were curatively treated with CRT. External beam radiotherapy (52 Gy/26 fractions) with elective groin irradiation (24 Gy) was applied in 2 series divided by a median gap of 12 days. Chemotherapy including fluorouracil and Mitomycin-C was delivered in two sequences. Long-term QOL was assessed using the site-specific EORTC QLQ-CR29 and the global QLQ-C30 questionnaires.
  
  
  RESULTS
  Five-year local control, colostomy-free survival, and overall survival were 78%, 94% and 80%, respectively. The global QOL score according to the QLQ-C30 was good with 70 out of 100. The QLQ-CR29 questionnaire revealed that 77% of patients were mostly satisfied with their body image. Significant anal pain or fecal incontinence was infrequently reported. Skin toxicity grade 3 or 4 was present in 76% of patients and erectile dysfunction was reported in 100% of male patients.
  
  
  CONCLUSIONS
  Short split-course CRT for anal carcinoma seems to be associated with good local control, survival and long-term global QOL. However, it is also associated with severe acute skin toxicity and sexual dysfunction. Implementation of modern techniques such as intensity-modulated radiation therapy (IMRT) might be considered to reduce toxicity.
authors.affiliation: Department of Radiation Oncology, Centre Hospitalier Universitaire de Montréal- Notre-Dame Hospital, Canada. sawyna.provencher@usherbrooke.ca
authors.forename: Sawyna
authors.initials: S
authors.lastname: Provencher
authors.forename: Christoph
authors.initials: C
authors.lastname: Oehler
authors.forename: Sophie
authors.initials: S
authors.lastname: Lavertu
authors.forename: Marjory
authors.initials: M
authors.lastname: Jolicoeur
authors.forename: Bernard
authors.initials: B
authors.lastname: Fortin
authors.forename: David
authors.initials: D
authors.lastname: Donath
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001005:Anus Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D011788:Quality of Life; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D016685:Mitomycin; D005472:Fluorouracil